![](/img/cover-not-exists.png)
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib
Wang, Wenjun, Bai, Wei, Wang, Enxin, Zhao, Yan, Liu, Lei, Yang, Man, Cai, Hongwei, Xia, Dongdong, Zhang, Lei, Niu, Jing, Yin, Zhanxin, Zhang, Zhuoli, Fan, Daiming, Xia, Jielai, Han, GuohongLanguage:
english
Journal:
International Journal of Cancer
DOI:
10.1002/ijc.30451
Date:
October, 2016
File:
PDF, 1.30 MB
english, 2016